News  ›  Article

Farris LLP: Vancouver's Law Firm


12 January 2015

Partner Hector MacKay-Dunn leads Farris Advisory Team in Tekmira-OnCore Merger

Jan. 11, 2015

Farris’ Tekmira Advisory Team included partners, Hector MacKay-Dunn, Q.C., Ronald Murray, Denise Nawata and Peter Roth, along with Ronald Chin, Melissa Mitchell, Allan McGavin, Nikki Alvarez, and Roja Safartabar; Marylee Davies (Employment), David Selley (Competition and Investment Canada), Teresa Tomchak (Securities Regulatory), and Thom Ciz (Tax).

To view the full press release please click here.

Tekmira Pharmaceuticals Corporation, a leading developer of RNA interference therapeutics, and OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, announced that they have agreed to merge to create a new leading global HBV company focused on developing a curative regimen for hepatitis B patients by combining multiple therapeutic approaches.

Under the terms of the agreement, the transaction will be carried out by way of a merger pursuant to which OnCore will merge with a wholly-owned subsidiary of Tekmira. Upon closing, stockholders of OnCore will hold approximately fifty percent (50%) of the total number of outstanding shares of capital stock of Tekmira. The implied market value of the combined company, based on the closing price of Tekmira common shares on the NASDAQ Global Market on January 9, 2015, is approximately USD$750 million.

‹ Back